Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 15pembrolizumab 12Capecitabine 12Fluorouracil 9Leucovorin 7Albumin-Bound Paclitaxel 7lenvatinib 6Radiofrequency Ablation 6Panitumumab 6130-nm albumin-bound paclitaxel 6Irinotecan 5Bevacizumab 5durvalumab 4Taxes 4Nivolumab 4Hepatectomy 4Drug Therapy 4tremelimumab 3apatinib 3Radiosurgery 3Platinum 3Injections 3Floxuridine 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3trametinib 2spartalizumab 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cholangiocarcinoma × olutasidenib × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡